Virus vaccine put to final test in thousands of volunteers

Virus vaccine put to final test in thousands of volunteers
Virus vaccine put to final test in thousands of volunteers

Virus vaccine put to final test in thousands of volunteers

The world’s largest COVID-19 vaccine study helped test the vaccines created by the U.S. government on Monday, the first of 30 million planned volunteers – one of the few candidates in the final stretch of the global vaccine race.

National Institutes of Health and Moderna Inc. There is still no guarantee that the experimental vaccine developed by will actually protect it.

Necessary evidence: Volunteers don’t know if they’re getting a real photo or a fake version. After two doses, scientists will closely monitor that they are experiencing more infections about their daily routines, especially in areas where the virus still spreads uncontrollably.


Dr. from NIH “Unfortunately, we have a lot of infections right now for the United States,” Anthony Fauci recently told the Associated Press.

Moderna said the vaccine was made in Savannah, Georgia, which first began among more than seven dozen test sites spread across the country.

Some other vaccines made earlier this month by the University of Oxford of China and the UK started smaller final stage tests in Brazil and other hard-hit countries.

However, the U.S. requires its own tests for any vaccine that can be used in the country and creates a high bar: In the autumn of each month, the state-funded COVID-19 Prevention Network will present a new study of a leading candidate – each with 30,000 newly hired volunteers.

Large studies are required not only to test whether the shots are working or not, but to check the safety of each potential vaccine. And following the same rules of work will allow scientists to finally compare all the shots.

Next August, the final run of the Oxford shot begins, then plans to test a candidate from Johnson & Johnson in September and Novavax in October – if they all go by schedule. Pfizer Inc. this summer, 30,000 people are planning their own work.

A striking number of people needed to roll up the sleeves for this science. But in recent weeks, more than 150,000 Americans have filled an online registry with interest, says virologist Dr at the Fred Hutchinson Cancer Research Institute in Seattle. Larry Corey helped control his workspaces.

“These trials have to be multi-generation, multiethnic, and reflect the diversity of the US population,” Corey said at a vaccination meeting last week. He stressed that it was particularly important to provide enough Black and Spanish participants, because these populations were very impressed by COVID-19.


It normally takes years to create a new vaccine from scratch, but scientists are breaking speed records this time, which is encouraged by the knowledge that vaccination is the best hope of the world against pandemics. It was not even known that the coronavirus existed before the end of December, and it took action on January 10 when vaccine makers shared the genetic sequence of the Chinese virus.

Only 65 days later, the NIH vaccine was tested in humans in March. The first buyer now encourages others to volunteer.

“We all feel very helpless right now. There is very little we can do to combat this virus. And being able to attend this hearing made me feel like I was doing something, ”said Seattle to Jennifer Haller AP. “Be prepared for a lot of questions for how you passed by your friends and family and a lot of thanks.”

This first-stage study involving Haller and 44 others showed that the shots enlivened the volunteers’ immune systems with some minor side effects at the injection site, such as short fever, chills, and pain, as scientists hoped would be protective. The early testing of other leading candidates has similarly encouraged results.

If everything went well in recent studies, Oxford’s monitoring will still take months after the Moderna test of the initial data.

Governments around the world are trying to stock millions of leading candidates, so vaccines can start immediately if regulators approve and approve one or more vaccines. But the first available doses will be rationalized, possibly leaving the virus for people at the highest risk.

Head of Moderna from Massachusetts “We are optimistic, cautiously optimistic,” Stephen Hoge told a House subcommittee last week that the vaccine will work and there will be data to be proven “towards the end of the year”. .

Until then, volunteer Haller, who returned in March, wears a mask among the public and takes the same distance measures recommended for everyone – and hopes that one of the shots in the pipeline will come out of the pan.

“I don’t know what the chance of getting this is the right vaccine. But thankfully, there are too many people struggling with this right now. ”